Ochre Bio and Boehringer Ingelheim Enter into a Collaboration to Develop and Commercialize Novel Regenerative Treatments for Advanced Liver Disease
Shots:
- In this multi-year, multi-target collaboration, Ochre Bio’s discovery platform combines machine learning with imaging and deep genomic phenotyping, RNA chemistry, and ex-vivo human-organ perfusion models to discover multiple novel regenerative targets for chronic liver diseases (CLDs)
- BI aims to develop a treatment that is capable of increasing the liver’s self-repair capability which could eventually reduce disease progression by modifying regenerative targets
- Ochre Bio will receive total deal value >$1B, includes $35M upfront and R&D milestone, and an undisclosed clinical, regulatory and commercial milestone, plus tiered royalties
Ref: Ochre Bio | Image: Ochre Bio
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
